Virginia's Gov. Terry McAuliffe said Thursday that UniTao Pharmaceuticals LLC has purchased the Boehringer Ingelheim plant that's slated to close by the end of the year.
AstraZeneca today announced that the FDA has approved once-daily XIGDUO™ XR (dapagliflozin and...
Pfizer announced that the FDA has granted accelerated approval of TRUMENBA ® (meningococcal...
Novo Nordisk has announced plans to hire up to 90 people at its newly-acquired manufacturing...
The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine. This is the first time in the current Ebola outbreak that EMA has given ‘rapid scientific advice’ using an accelerated procedure.
In a letter Tuesday to key congressional committees, the National Association of Medicaid Directors said lawmakers should consider everything from outright price controls on manufacturers to federal help for states trying to pay for the new medications.
In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company are changing the operational and financial structure of their diabetes alliance in certain countries.
Sanofi sacked its CEO Wednesday following a board room rift over the handling of one of France's largest publicly traded companies. Christopher Viehbacher, the first non-Frenchman to lead Sanofi, was dismissed after six years running the company that traces its roots to the early 19th century.
Amgen said Monday that its earnings fell in the third quarter on charges from an ongoing restructuring effort, but the biotech drugmaker's adjusted results still surpassed Wall Street expectations.
Sanofi saw its stock price plunge today after it reported a slide in quarterly earnings and warned of pricing pressure on its blockbuster diabetes treatment in the U.S. Sanofi shares fell 8.4 percent to 76.39 euros, forfeiting gains in the run-up to the announcement.
On a per-share basis, the New York-based company said it had profit of 42 cents. Earnings, adjusted for non-recurring costs and to account for discontinued operations, were 57 cents per share.
The Swiss agency that regulates new drugs has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization.
Novartis AG has posted a 45 percent rise in net profit in the third quarter, boosted by strong sales of new products such as Gilenya for multiple sclerosis and the leukemia drug Tasigna. The Basel, Switzerland-based company's reported quarterly net profit was $3.24B
GlaxoSmithKline Third Quarter 2014 Results Interview with CEO Sir Andrew Witty & CFO Simon Dingemans.October 27, 2014 9:07 am | Videos | Comments
Interview with Sir Andrew Witty, CEO, and Simon Dingemans, CFO announcing the company's Q3 2014 results including a restructuring of the business and a possible partial IPO of ViiV Healthcare.
CSL Limited today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million. The business will be combined with CSL's subsidiary, bioCSL.
Merck's third-quarter net income fell mostly because of large costs tied to acquisitions and divestitures. But the company's adjusted earnings topped Wall Street's view, and it narrowed its full-year adjusted earnings forecast on Monday.
Valeant Pharmaceuticals International says it will raise its offer for Botox maker Allergan to $200 or more per share. Valeant made the statement in a letter to Allergan's board released publicly seeking to urge Allergan to talk about an acquisition.
Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.
The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. Still, the agency warned it's not clear whether any of these will work against the deadly virus that has...
Bristol-Myers Squibb reported third-quarter profit of $721 million. The New York-based company said it had profit of 43 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The results beat Wall Street expectations.
Pfizer says it approved the repurchase of $11 billion in company stock. The company did not say when it would buy back the shares. Pfizer has $1.3 billion remaining from its latest stock repurchase program.
Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant Cymbalta lost patent protection and faced competition from less-expensive generics. Lilly said its revenue from Cymbalta plunged 73%t and revenue from the osteoporosis treatment Evista fell 65%.
Pfizer announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.
The companies announced a team-up in January but did not disclose terms. Without explaining the initial terms of the partnership, the companies said Zymeworks could get an additional $375M in milestones and other payments.
The company confirmed there was a case of progressive multifocal leukoencephalopathy, or PML, in one patient who took the drug Tecfidera. It said the patient recently died of complications of pneumonia.
Biogen Idec has reported third quarter 2014 results, including revenue of $2.5B, a 37% increase compared to the third quarter of 2013. Third quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.80, an increase of 61% over the third quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the third quarter was $900M, an increase of 60% over the third quarter of 2013.
The recent FDA approval of Harvoni, Gilead Sciences’ once-daily, single-tablet regimen to treat chronic hepatitis C virus genotype 1 infection in adults, will enable the company to maintain its dominance in an increasingly competitive market, says an analyst with research and consulting firm GlobalData.
An increase in the number of prescriptions of a powerful antipsychotic drug for conditions not approved by Health Canada is raising concern about what medical experts call lack of professional and government oversight of doctors' prescribing practices.
A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker's top shareholders.
- Page 1